Cargando…

Vogt-Koyanagi-Harada disease occurring during pegylated interferon-α2b and ribavirin combination therapy for chronic hepatitis C

Vogt-Koyanagi-Harada (VKH) disease is a multisystem syndrome characterized by ocular (uveitis and retinal detachment), neurological (headache, tinnitus, and meningitis), and integumentary (vitiligo, alopecia, and poliosis) involvement. Although the pathogenesis of VKH disease is not well understood,...

Descripción completa

Detalles Bibliográficos
Autores principales: Lim, Jae Hee, Lee, Yun Nah, Kim, Young Seok, Kim, Sang Gyune, Jeong, Seung Won, Jang, Jae Young, Kim, Hong Soo, Lee, Sae Hwan, Park, Tae Kwann
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Association for the Study of the Liver 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3304626/
https://www.ncbi.nlm.nih.gov/pubmed/21494079
http://dx.doi.org/10.3350/kjhep.2011.17.1.61
_version_ 1782226917979586560
author Lim, Jae Hee
Lee, Yun Nah
Kim, Young Seok
Kim, Sang Gyune
Jeong, Seung Won
Jang, Jae Young
Kim, Hong Soo
Lee, Sae Hwan
Park, Tae Kwann
author_facet Lim, Jae Hee
Lee, Yun Nah
Kim, Young Seok
Kim, Sang Gyune
Jeong, Seung Won
Jang, Jae Young
Kim, Hong Soo
Lee, Sae Hwan
Park, Tae Kwann
author_sort Lim, Jae Hee
collection PubMed
description Vogt-Koyanagi-Harada (VKH) disease is a multisystem syndrome characterized by ocular (uveitis and retinal detachment), neurological (headache, tinnitus, and meningitis), and integumentary (vitiligo, alopecia, and poliosis) involvement. Although the pathogenesis of VKH disease is not well understood, an autoimmune T-cell response to a melanocyte-associated antigen is considered to be a cause of VKH disease. The complex immunological response to interferon and ribavirin may induce or exacerbate the autoimmune condition; however, VKH disease is a very rare complication associated with interferon therapy in chronic hepatitis C. We report a case of VKH disease occurring during pegylated interferon-α2b and ribavirin combination therapy for chronic hepatitis C.
format Online
Article
Text
id pubmed-3304626
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher The Korean Association for the Study of the Liver
record_format MEDLINE/PubMed
spelling pubmed-33046262012-03-20 Vogt-Koyanagi-Harada disease occurring during pegylated interferon-α2b and ribavirin combination therapy for chronic hepatitis C Lim, Jae Hee Lee, Yun Nah Kim, Young Seok Kim, Sang Gyune Jeong, Seung Won Jang, Jae Young Kim, Hong Soo Lee, Sae Hwan Park, Tae Kwann Korean J Hepatol Case Report Vogt-Koyanagi-Harada (VKH) disease is a multisystem syndrome characterized by ocular (uveitis and retinal detachment), neurological (headache, tinnitus, and meningitis), and integumentary (vitiligo, alopecia, and poliosis) involvement. Although the pathogenesis of VKH disease is not well understood, an autoimmune T-cell response to a melanocyte-associated antigen is considered to be a cause of VKH disease. The complex immunological response to interferon and ribavirin may induce or exacerbate the autoimmune condition; however, VKH disease is a very rare complication associated with interferon therapy in chronic hepatitis C. We report a case of VKH disease occurring during pegylated interferon-α2b and ribavirin combination therapy for chronic hepatitis C. The Korean Association for the Study of the Liver 2011-03 2011-03-21 /pmc/articles/PMC3304626/ /pubmed/21494079 http://dx.doi.org/10.3350/kjhep.2011.17.1.61 Text en Copyright © 2011 by The Korean Association for the Study of the Liver http://creativecommons.org/licenses/by-nc/3.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Lim, Jae Hee
Lee, Yun Nah
Kim, Young Seok
Kim, Sang Gyune
Jeong, Seung Won
Jang, Jae Young
Kim, Hong Soo
Lee, Sae Hwan
Park, Tae Kwann
Vogt-Koyanagi-Harada disease occurring during pegylated interferon-α2b and ribavirin combination therapy for chronic hepatitis C
title Vogt-Koyanagi-Harada disease occurring during pegylated interferon-α2b and ribavirin combination therapy for chronic hepatitis C
title_full Vogt-Koyanagi-Harada disease occurring during pegylated interferon-α2b and ribavirin combination therapy for chronic hepatitis C
title_fullStr Vogt-Koyanagi-Harada disease occurring during pegylated interferon-α2b and ribavirin combination therapy for chronic hepatitis C
title_full_unstemmed Vogt-Koyanagi-Harada disease occurring during pegylated interferon-α2b and ribavirin combination therapy for chronic hepatitis C
title_short Vogt-Koyanagi-Harada disease occurring during pegylated interferon-α2b and ribavirin combination therapy for chronic hepatitis C
title_sort vogt-koyanagi-harada disease occurring during pegylated interferon-α2b and ribavirin combination therapy for chronic hepatitis c
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3304626/
https://www.ncbi.nlm.nih.gov/pubmed/21494079
http://dx.doi.org/10.3350/kjhep.2011.17.1.61
work_keys_str_mv AT limjaehee vogtkoyanagiharadadiseaseoccurringduringpegylatedinterferona2bandribavirincombinationtherapyforchronichepatitisc
AT leeyunnah vogtkoyanagiharadadiseaseoccurringduringpegylatedinterferona2bandribavirincombinationtherapyforchronichepatitisc
AT kimyoungseok vogtkoyanagiharadadiseaseoccurringduringpegylatedinterferona2bandribavirincombinationtherapyforchronichepatitisc
AT kimsanggyune vogtkoyanagiharadadiseaseoccurringduringpegylatedinterferona2bandribavirincombinationtherapyforchronichepatitisc
AT jeongseungwon vogtkoyanagiharadadiseaseoccurringduringpegylatedinterferona2bandribavirincombinationtherapyforchronichepatitisc
AT jangjaeyoung vogtkoyanagiharadadiseaseoccurringduringpegylatedinterferona2bandribavirincombinationtherapyforchronichepatitisc
AT kimhongsoo vogtkoyanagiharadadiseaseoccurringduringpegylatedinterferona2bandribavirincombinationtherapyforchronichepatitisc
AT leesaehwan vogtkoyanagiharadadiseaseoccurringduringpegylatedinterferona2bandribavirincombinationtherapyforchronichepatitisc
AT parktaekwann vogtkoyanagiharadadiseaseoccurringduringpegylatedinterferona2bandribavirincombinationtherapyforchronichepatitisc